HLS Therapeutics Inc.

TSX:HLS.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$3.76 -2.51%

-$0.11 today

Market cap
$116.32M
Beta
0.85
P/E (TTM)
-9.6
EPS (TTM)
-$0.33
52W Low $0.00High $5.77

Volume 0.04M

Average 0.01M

HLS.TO Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

HLS Therapeutics Inc.TSX: HLS.TO

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 36.1%

Gross margin was 36.1% in Q1 FY2026, down 44.9 pp from a year earlier. On a trailing-twelve-month basis it was 61.7%, down 21.3 pp year over year. Over 3 fiscal years it narrowed by 49.4 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
36.1%-10.5 pp QoQ
Last fiscal yearDec 2025
42.5%-41.6 pp YoY
LTMMar 2026
61.7%-21.3 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-44.9 pp——
1 year-41.6 pp——
3 years-49.4 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
42.5%
Year-over-year change
-41.6pp

Gross Margin vs competitors

How HLS.TO compares with its peers on the latest reported figures

  • HLS.TO's LTM Mar 2026 gross margin of 61.7% is the 4th highest of the 6 companies compared; the peer median is 63.5%.
  • Its year-over-year change of -21.3 pp is the lowest of 6, against a peer median of -1.4 pp.
  • Over three fiscal years its change of -49.4 pp compares with a peer median of +1.9 pp.
HLS.TO Competitors Peer median
Gross Margin for HLS.TO and competitors
Company Period LTM level YoY 3-year change
CPIXCumberland Pharmaceuticals Inc.LTM Mar 202682.9% -1.4 pp+6.7 pp
BHCBausch Health Companies Inc.LTM Jun 202671.8% +1.1 pp-0.3 pp
AQSTAquestive Therapeutics, Inc.LTM Mar 202663.5% -4.9 pp+2.1 pp
HLS.TOHLS Therapeutics Inc.LTM Mar 202661.7% -21.3 pp-49.4 pp
ETONEton Pharmaceuticals, Inc.LTM Mar 202654.8% -3.7 pp-13.9 pp
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 202639.3% +1.7 pp+1.9 pp
NERVMinerva Neurosciences, Inc.FY2025— ——
Peer median (excluding HLS.TO) 63.5%-1.4 pp+1.9 pp

Competitors are the stored peer set for HLS.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue60.01M61.47M63.07M56.62M56.47M
Cost of Revenue3.97M4.98M7.62M9M32.46M
Gross Profit56.04M56.49M55.45M47.62M24.01M
Gross Margin93.4%91.9%87.9%84.1%42.5%
Research & Development00000
Selling, General & Admin32.06M35.58M28.29M26.93M22M
Operating Expenses62.32M69.98M55.45M55.31M28.19M
Depreciation & Amortization30.26M34.4M31.94M22.72M22.2M
EBITDA25.41M18M12.88M17.22M18.02M
EBITDA Margin42.3%29.3%20.4%30.4%31.9%
Operating Income(6.24M)(13.44M)(10.35M)(7.69M)(4.18M)
Operating Margin-10.4%-21.9%-16.4%-13.6%-7.4%
Interest Income44K57K350K319K108.87K
Interest Expense6.96M7.32M8.75M10.08M7.22M
Other Income / Expenses(5.52M)(10.23M)(17.45M)(7.9M)(8.92M)
Income Before Tax(11.81M)(23.72M)(27.8M)(15.58M)(13.1M)
Pre-Tax Margin-19.7%-38.6%-44.1%-27.5%-23.2%
Income Tax Expense1.31M(124K)(272K)4.07M(452.79K)
Net Income(13.12M)(23.6M)(27.53M)(19.66M)(12.65M)
Net Margin-21.9%-38.4%-43.6%-34.7%-22.4%
EPS (Basic)(0.41)(0.73)(0.85)(0.62)(0.40)
EPS (Diluted)(0.41)(0.73)(0.85)(0.62)(0.40)
Weighted Avg Shares32.18M32.33M32.26M31.84M31.53M
Weighted Avg Shares (Diluted)32.18M32.43M32.26M31.84M31.53M

HLS Therapeutics Inc.

TSX:HLS.TO

Intrinsic Alpha fair value

Locked

Current Price

$3.76

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.